| Autor: |
Takeshi Hatanaka, Takashi Kosone, Naoto Saito, Satoshi Takakusagi, Hiroki Tojima, Atsushi Naganuma, Hitoshi Takagi, Toshio Uraoka, Satoru Kakizaki |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
JGH Open, Vol 5, Iss 10, Pp 1183-1189 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2397-9070 |
| DOI: |
10.1002/jgh3.12650 |
| Popis: |
Abstract Background and Aim This retrospective study investigated the effect of 48‐week pemafibrate therapy in non‐alcoholic fatty liver disease (NAFLD) with hypertriglyceridemia, as evaluated by the FibroScan‐aspartate aminotransferase (FAST) score. Methods A total of 31 NAFLD patients who were treated with pemafibrate in Gunma Saiseikai Maebashi Hospital and Kusunoki Hospital from September 2018 to April 2020 were included in the current study. We used the FAST score, which is a novel index of steatohepatitis that can be calculated based on the AST value, controlled attenuation parameter (CAP), and liver stiffness measurement (LSM), to evaluate the effect of pemafibrate treatment. Results The median age was 64.0 (interquartile range [IQR] 55.0–75.0) years and 14 patients (45.2%) were male. Median body mass index was 26.8 (IQR 23.8–28.8). Hypertension and diabetes mellitus were detected in 14 (45.2%) and five (16.1%) patients, respectively. Fasting triglyceride and high‐density lipoprotein cholesterol were significantly improved (P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text